June 2026 in “British Journal of Dermatology” Amivantamab treatment often causes skin issues that can affect quality of life and treatment continuation.
7 citations
,
December 2021 in “Curēus” Breast cancer skin metastases are rare, look different, and can be confused with other skin issues, so a biopsy is needed for accurate diagnosis.
1 citations
,
October 2022 in “Дерматовенерология Косметология” EGFR inhibitors for lung cancer can cause severe skin issues.
July 2024 in “Open Repository of the University of Porto (University of Porto)” Dutasteride is more effective than finasteride for hair growth, and pregabalin effectively treats neuropathic pain.
January 2025 in “Journal of Education Health and Sport” More effective methods are needed to prevent hair loss from chemotherapy.
October 2014 in “Archives of disease in childhood” Childhood cancer diagnosis leads to long-term physical and emotional health issues in parents.
11 citations
,
July 2024 in “Cancers” Preventing and managing skin issues from cancer treatment is crucial, especially in high UV areas like Australia and New Zealand.
January 2016 in “Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München)” FDG PET/CT can improve cancer treatment plans in dogs.
March 2026 in “Pharmaceuticals” Reporter characteristics affect detection of hair loss from cancer therapy.
February 2010 in “Acta Obstetricia et Gynecologica Scandinavica” The issue covers reproductive health topics like cancer markers, incontinence treatments, and the impact of pre-term birth.
Permanent micropigmentation can help cancer survivors feel better about themselves by restoring eyebrows lost during chemotherapy.
42 citations
,
January 2018 in “Expert review of precision medicine and drug development” Drug repositioning is becoming more targeted and efficient with new technologies, offering personalized treatment options and growing interest in the field.
August 2018 in “SDÜ SAĞLIK BİLİMLERİ DERGİSİ” No method fully prevents hair loss from chemotherapy, but some methods can reduce it and improve quality of life.
New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.
30 citations
,
March 2007 in “Expert opinion on drug safety” Cetuximab often causes skin rashes, and managing these is important for cancer treatment.
March 1965 in “Hospital Topics” Chemotherapy provides symptom relief and extends life in 30-50% of gynecological cancer cases, but has only cured choriocarcinoma.
January 2004 in “Oncology Times” Cancer myths can harm treatment and prevention efforts.
1 citations
,
September 2005 in “Oncology times” Wearing a frozen glove during chemotherapy can reduce nail and skin problems but may not be comfortable for everyone.
1 citations
,
February 2002 in “Oncology Times” Intravenous arsenic is safe and effective for treating certain blood cancers.
February 2004 in “Oncology Times” Green tea extract and cycling hormone treatments may help treat advanced prostate cancer.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
65 citations
,
February 2015 in “Neuro-Oncology” Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
June 2026 in “Pathology & Oncology Research” Scalp cooling helps prevent hair loss during certain breast cancer treatments, especially when anthracyclines aren't used.
February 2020 in “Oncology Times” Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.
November 2019 in “Neuro-oncology” Rind-based techniques can lower scalp radiation dose and reduce hair loss in brain cancer treatment.
October 2018 in “Oncology Times” Hair is important for aging and cancer treatment, affecting emotions, culture, and health.
November 2004 in “Oncology Times” Advocacy groups should avoid marketing partnerships that may imply drug endorsements.
March 2003 in “Oncology Times” Further research is needed to develop effective cancer prevention strategies.
November 2001 in “Oncology Times” The committee decided not to approve the drug due to low effectiveness and high risks.
1 citations
,
November 2024 in “Neuro-Oncology” Temozolomide can cause severe bone marrow suppression, leading to life-threatening complications.